LEADER 04323nam 22010933a 450 001 9910367751403321 005 20250203235433.0 010 $a9783039215836 010 $a3039215833 024 8 $a10.3390/books978-3-03921-583-6 035 $a(CKB)4100000010106203 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/53824 035 $a(ScCtBLL)5fc187e9-5edd-4bb3-99d9-ba19ad58202b 035 $a(OCoLC)1163845405 035 $a(oapen)doab53824 035 $a(EXLCZ)994100000010106203 100 $a20250203i20192019 uu 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aMolecular Basis of Cardiovascular Diseases : $eImplications of Natriuretic Peptides /$fSperanza Rubattu, Massimo Volpe 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 210 1$aBasel, Switzerland :$cMDPI,$d2019. 215 $a1 electronic resource (212 p.) 311 08$a9783039215829 311 08$a3039215825 330 $aThe natriuretic peptides (NPs) family includes a class of hormones and their receptors needed for the physiological control of cardiovascular functions. The discovery of NPs provided a fundamental contribution into our understanding of the physiological regulation of blood pressure, and of heart and kidney functions. NPs have also been implicated in the pathogenesis of several cardiovascular diseases (CVDs), including hypertension, atherosclerosis, heart failure, and stroke. A fine comprehension of the molecular mechanisms dependent from NPs and underlying the promotion of cardiovascular damage has contributed to improve our understanding of the molecular basis of all major CVDs. Finally, the opportunity to target NPs in order to develop new therapeutic tools for a better treatment of CVDs has been developed over the years. The current Special Issue of the Journal covers all major aspects of the molecular implications of NPs in physiology and pathology of the cardiovascular system, including NP-based therapeutic approaches. 606 $aMedicine$2bicssc 610 $apostmortem biochemistry 610 $amedulla 610 $aanimal models 610 $aremodeling 610 $aBNP 610 $aPCSK9 610 $aguanylyl cyclase/natriuretic peptide receptor-A 610 $acardiorenal syndrome 610 $aforensic medicine 610 $apreserved ejection fraction 610 $akidney 610 $arenin-angiotensin-aldosterone system 610 $aatrial fibrillation 610 $avasopressor 610 $acongestive heart failure 610 $aatrial natriuretic peptide 610 $agene-knockout 610 $aobesity 610 $aheart failure 610 $aangiogenesis 610 $aadipose tissue 610 $avascular 610 $aLDL receptor 610 $ametabolic syndrome 610 $alinkage analysis 610 $acardiometabolic disease 610 $acardiomyocyte 610 $acardiac dysfunction 610 $acardiac hypertrophy 610 $ainsulin 610 $alipid metabolism 610 $acGMP 610 $aIdiopathic Pulmonary Arterial Hypertension (IPAH) 610 $aNatriuretic Peptide Clearance Receptor (NPR-C) signaling 610 $agene-duplication 610 $arenin?angiotensin system 610 $anatriuretic peptides 610 $aangiotensin receptor?neprilysin inhibitor 610 $acardiac remodelling 610 $aARNi 610 $aNT-proBNP 610 $ainflammation 610 $apulmonary arterial hypertension 610 $avascular homeostasis 610 $aendothelial cell 610 $aAtrial Natriuretic peptide 610 $anatriuretic peptide 610 $avasodilator 610 $astroke 610 $agenetic variants 610 $aarterial hypertension 610 $afibroblast 610 $aMANP 610 $ahypertension 610 $aguanylyl cyclase receptor A 615 7$aMedicine 700 $aRubattu$b Speranza$01324890 702 $aVolpe$b Massimo 801 0$bScCtBLL 801 1$bScCtBLL 906 $aBOOK 912 $a9910367751403321 996 $aMolecular Basis of Cardiovascular Diseases$94318014 997 $aUNINA